[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fCKRafsQnEv0Xkp0wXn3-_1g3HTONDZXI3BQ1MYp4nf0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":80,"rows":87},"Danish Headache Center",[4],129,false,13,2,8098,6,43,[14,17,20,23,26,29,32,34],{"name":15,"count":16},"Migraine",36,{"name":18,"count":19},"Headache",29,{"name":21,"count":22},"Migraine Without Aura",18,{"name":24,"count":25},"Headache, Migraine",11,{"name":27,"count":28},"Post-Traumatic Headache",9,{"name":30,"count":31},"Migraine With Aura",8,{"name":33,"count":31},"Headache Disorders",{"name":35,"count":36},"Healthy",7,[38,43,48,52,57,62,67,71,76],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06632080","Effects of Substance P on Headache Induction in Healthy Individuals","2025-12-31","Substance P",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06839118","Safety and Efficacy of Botulinum Toxin A in Patients With Posttraumatic Headache","2026-03-01","Botox 200 UNT",{"nctId":49,"briefTitle":50,"date":51,"intervention":42},"NCT06959004","Substance P-Induced Migraine Attacks Without Aura","2026-05-01",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07021859","Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide","2026-06-01","Calcitonin-gene related peptide",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07342296","Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38","2026-12-01","Pituitary Adenylate Cyclase Activating Polypeptide-38",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07451769","Selective Activation of the Adrenomedullin Receptors in Migraine","2027-03-10","Adrenomedullin",{"nctId":68,"briefTitle":69,"date":70,"intervention":66},"NCT07059546","Hypersensitivity to Adrenomedullin in Post-Traumatic Headache","2028-05-01",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07340788","Amylin-Induced Migraine Attacks Without Aura","2028-10-30","Amylin",{"nctId":77,"briefTitle":78,"date":79,"intervention":75},"NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","2028-12",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,113,148,173,207,238,270,296,314,339,365,389,415,438,461,484,608,690,744,799,853,897,947,981,1014,1038,1066,1092,1123,1154,1178,1196,1221,1243,1265,1289,1307,1331,1354,1377,1395,1417,1441,1459,1483,1508,1530,1552,1570,1588,1612,1630,1648,1671,1689,1707,1728,1751,1774,1797,1815,1837,1862],{"intervention":47,"totalTrials":89,"cells":90},1,{"EARLY_PHASE1":91,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":109,"NA":111},{"trials":92,"activeCount":93},[],0,{"trials":95,"activeCount":93},[],{"trials":97,"activeCount":93},[],{"trials":99,"activeCount":89,"soonestReadout":46},[100],{"nctId":44,"briefTitle":45,"status":101,"phases":102,"primaryCompletion":46,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":108},"RECRUITING",[84],"2026-08-01","2025-01-10",80,[107],"Posttraumatic Headache",[47],{"trials":110,"activeCount":93},[],{"trials":112,"activeCount":93},[],{"intervention":66,"totalTrials":9,"cells":114},{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":121,"PHASE4":123,"NA":125},{"trials":116,"activeCount":93},[],{"trials":118,"activeCount":93},[],{"trials":120,"activeCount":93},[],{"trials":122,"activeCount":93},[],{"trials":124,"activeCount":93},[],{"trials":126,"activeCount":9,"soonestReadout":65},[127,141],{"nctId":63,"briefTitle":64,"status":128,"phases":129,"primaryCompletion":65,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":140},"NOT_YET_RECRUITING",[86],"2032-12-20","2026-03-10",26,[15,134,135,66,136,137,138,139],"Brain Diseases","Central Nervous System Diseases","Pain","Peptides","Neuropeptides","Signs and Symptoms",[66],{"nctId":68,"briefTitle":69,"status":101,"phases":142,"primaryCompletion":70,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":147},[86],"2028-12-01","2025-08-01",21,[107],[66],{"intervention":42,"totalTrials":9,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":158,"NA":160},{"trials":151,"activeCount":93},[],{"trials":153,"activeCount":93},[],{"trials":155,"activeCount":93},[],{"trials":157,"activeCount":93},[],{"trials":159,"activeCount":93},[],{"trials":161,"activeCount":9,"soonestReadout":41},[162,167],{"nctId":49,"briefTitle":50,"status":101,"phases":163,"primaryCompletion":51,"completion":60,"start":164,"enrollment":145,"conditions":165,"interventions":166},[86],"2025-05-13",[15],[42],{"nctId":39,"briefTitle":40,"status":128,"phases":168,"primaryCompletion":41,"completion":41,"start":169,"enrollment":145,"conditions":170,"interventions":172},[86],"2024-10-14",[171],"Healthy Volunteers Only",[42],{"intervention":75,"totalTrials":9,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":185},{"trials":176,"activeCount":93},[],{"trials":178,"activeCount":93},[],{"trials":180,"activeCount":93},[],{"trials":182,"activeCount":93},[],{"trials":184,"activeCount":93},[],{"trials":186,"activeCount":9,"soonestReadout":74},[187,202],{"nctId":72,"briefTitle":73,"status":128,"phases":188,"primaryCompletion":74,"completion":74,"start":189,"enrollment":145,"conditions":190,"interventions":201},[86],"2026-02",[191,33,134,192,135,193,139,194,195,18,136,196,197,198,137,199,75,200],"Headache Disorders, Primary","Nervous System Diseases","Neurologic Manifestations","Pathological Conditions, Signs and Symptoms","Migraine Disorders","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Amino Acids, Peptides, and Proteins","Pramlintide",[75],{"nctId":77,"briefTitle":78,"status":128,"phases":203,"primaryCompletion":79,"completion":79,"start":189,"enrollment":145,"conditions":204,"interventions":206},[86],[205,134,33,192,135,193,139,194,27,136,196,197,198,137,199,75,200],"Headache Disorders, Secondary",[75],{"intervention":208,"totalTrials":9,"cells":209},"Pituitary adenylate cyclase activating polypeptide-38",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":220},{"trials":211,"activeCount":93},[],{"trials":213,"activeCount":93},[],{"trials":215,"activeCount":93},[],{"trials":217,"activeCount":93},[],{"trials":219,"activeCount":93},[],{"trials":221,"activeCount":89,"soonestReadout":60},[222,231],{"nctId":223,"briefTitle":224,"status":225,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":145,"conditions":229,"interventions":230},"NCT05378061","Hypersensitivity to PACAP-38 in Post-Traumatic Headache","UNKNOWN",[86],"2023-12-31","2022-06-16",[27],[208],{"nctId":58,"briefTitle":59,"status":128,"phases":232,"primaryCompletion":60,"completion":233,"start":234,"enrollment":145,"conditions":235,"interventions":237},[86],"2026-12-30","2026-02-01",[30,236],"Migraine Aura",[61],{"intervention":239,"totalTrials":9,"cells":240},"Calcitonin-Gene Related Peptide",{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":242,"activeCount":93},[],{"trials":244,"activeCount":93},[],{"trials":246,"activeCount":93},[],{"trials":248,"activeCount":93},[],{"trials":250,"activeCount":93},[],{"trials":252,"activeCount":89,"soonestReadout":55},[253,265],{"nctId":254,"briefTitle":255,"status":256,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT02466334","CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients","COMPLETED",[86],"2017-03","2018-12","2015-06",37,[263],"Cluster Headache",[239],{"nctId":53,"briefTitle":54,"status":101,"phases":266,"primaryCompletion":55,"completion":233,"start":267,"enrollment":145,"conditions":268,"interventions":269},[86],"2025-06-27",[236,30],[56],{"intervention":271,"totalTrials":89,"cells":272},"Diclofenac Potassium 50Mg\u002FPkt Oral Pwdr",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":294},{"trials":274,"activeCount":93},[],{"trials":276,"activeCount":93},[],{"trials":278,"activeCount":93},[],{"trials":280,"activeCount":93},[],{"trials":282,"activeCount":93},[283],{"nctId":284,"briefTitle":285,"status":286,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT05211154","Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine","TERMINATED",[85],"2025-04-30","2022-05-05",300,[30,21],[271,293],"Rimegepant 75 MG",{"trials":295,"activeCount":93},[],{"intervention":293,"totalTrials":89,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":312},{"trials":299,"activeCount":93},[],{"trials":301,"activeCount":93},[],{"trials":303,"activeCount":93},[],{"trials":305,"activeCount":93},[],{"trials":307,"activeCount":93},[308],{"nctId":284,"briefTitle":285,"status":286,"phases":309,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":310,"interventions":311},[85],[30,21],[271,293],{"trials":313,"activeCount":93},[],{"intervention":315,"totalTrials":89,"cells":316},"memantine",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":335,"NA":337},{"trials":318,"activeCount":93},[],{"trials":320,"activeCount":93},[],{"trials":322,"activeCount":93},[],{"trials":324,"activeCount":93},[325],{"nctId":326,"briefTitle":327,"status":256,"phases":328,"primaryCompletion":329,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":334},"NCT00315666","Prophylactic Effect of Memantine in Chronic Tension-Type Headache",[84],"2007-06","2006-05",40,[333],"Tension-Type Headache",[315],{"trials":336,"activeCount":93},[],{"trials":338,"activeCount":93},[],{"intervention":340,"totalTrials":89,"cells":341},"AMG 334",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":343,"activeCount":93},[],{"trials":345,"activeCount":93},[],{"trials":347,"activeCount":93},[348],{"nctId":349,"briefTitle":350,"status":256,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":354,"conditions":355,"interventions":358},"NCT03974360","Efficacy and Tolerability of Erenumab in the Prophylactic Treatment of Persistent Post-Traumatic Headache",[83],"2019-12-31","2019-04-05",100,[27,356,357],"Mild Traumatic Brain Injury","Post-Concussion Syndrome",[340],{"trials":360,"activeCount":93},[],{"trials":362,"activeCount":93},[],{"trials":364,"activeCount":93},[],{"intervention":366,"totalTrials":89,"cells":367},"NXN-188",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":369,"activeCount":93},[],{"trials":371,"activeCount":93},[],{"trials":373,"activeCount":93},[374],{"nctId":375,"briefTitle":376,"status":225,"phases":377,"primaryCompletion":378,"completion":379,"start":380,"enrollment":331,"conditions":381,"interventions":382},"NCT00877838","Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura",[83],"2010-03","2010-12","2009-05",[30],[366],{"trials":384,"activeCount":93},[],{"trials":386,"activeCount":93},[],{"trials":388,"activeCount":93},[],{"intervention":390,"totalTrials":89,"cells":391},"Placebos",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":409,"PHASE4":411,"NA":413},{"trials":393,"activeCount":93},[],{"trials":395,"activeCount":93},[],{"trials":397,"activeCount":93},[398],{"nctId":399,"briefTitle":400,"status":225,"phases":401,"primaryCompletion":402,"completion":403,"start":404,"enrollment":105,"conditions":405,"interventions":407},"NCT04054024","Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia",[83],"2021-10","2021-10-01","2019-10-28",[406],"Trigeminal Neuralgia",[408,390],"Erenumab",{"trials":410,"activeCount":93},[],{"trials":412,"activeCount":93},[],{"trials":414,"activeCount":93},[],{"intervention":416,"totalTrials":89,"cells":417},"BGC20-1531",{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":419,"activeCount":93},[],{"trials":421,"activeCount":93},[],{"trials":423,"activeCount":93},[424],{"nctId":425,"briefTitle":426,"status":256,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":31,"conditions":430,"interventions":431},"NCT00957983","EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model",[82,83],"2010-02","2009-08",[24],[416],{"trials":433,"activeCount":93},[],{"trials":435,"activeCount":93},[],{"trials":437,"activeCount":93},[],{"intervention":439,"totalTrials":89,"cells":440},"PGI2",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":442,"activeCount":93},[],{"trials":444,"activeCount":93},[445],{"nctId":446,"briefTitle":447,"status":286,"phases":448,"start":449,"enrollment":450,"conditions":451,"interventions":452},"NCT00291395","PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers",[82],"2005-09",12,[18,15],[439],{"trials":454,"activeCount":93},[],{"trials":456,"activeCount":93},[],{"trials":458,"activeCount":93},[],{"trials":460,"activeCount":93},[],{"intervention":462,"totalTrials":89,"cells":463},"L-kynurenine",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":465,"activeCount":93},[],{"trials":467,"activeCount":93},[468],{"nctId":469,"briefTitle":470,"status":256,"phases":471,"primaryCompletion":472,"completion":472,"start":473,"enrollment":11,"conditions":474,"interventions":475},"NCT03212430","The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers",[82],"2019-01-20","2017-03-01",[18],[462],{"trials":477,"activeCount":93},[],{"trials":479,"activeCount":93},[],{"trials":481,"activeCount":93},[],{"trials":483,"activeCount":93},[],{"intervention":485,"totalTrials":450,"cells":486},"Levcromakalim",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":488,"activeCount":93},[],{"trials":490,"activeCount":93},[],{"trials":492,"activeCount":93},[],{"trials":494,"activeCount":93},[],{"trials":496,"activeCount":93},[],{"trials":498,"activeCount":93},[499,508,518,529,537,546,555,565,575,583,591,599],{"nctId":500,"briefTitle":501,"status":256,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":507},"NCT05889442","Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab",[86],"2023-06-12","2023-03-09",16,[21],[485],{"nctId":509,"briefTitle":510,"status":256,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT05093582","The Effects of Levcromakalim in Patients With Cluster Headache",[86],"2022-09-27","2021-06-04",41,[263],[485,517],"Saline",{"nctId":519,"briefTitle":520,"status":225,"phases":521,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":528},"NCT03886922","The Hemodynamics Effect of Glibenclamide on Levcromakalim Assessed by High Resolution Magnetic Resonance Angiography (MRA) Technique in a Randomized Double-blind Cross-over Placebo-controlled Study With Healthy Volunteers",[86],"2023-08-30","2019-04-01",15,[526,18,527],"Hemodynamics of Cranial Arteries","Cerebral Blood Flow",[485,517],{"nctId":530,"briefTitle":531,"status":256,"phases":532,"primaryCompletion":472,"completion":472,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT03726242","Peripheral Nociceptive Effects of Levcromakalim",[86],"2018-11-01",20,[136,485],[485,517],{"nctId":538,"briefTitle":539,"status":256,"phases":540,"primaryCompletion":541,"completion":541,"start":542,"enrollment":534,"conditions":543,"interventions":545},"NCT03609008","The Effect of Levcromakalim Infusion on the Cranial Arteries Over Several Hours Using a High Resolution MRA Technique in a Randomized, Double-blind Placebo-controlled Design in Healthy Volunteers.",[86],"2018-08-15","2018-06-26",[544,18],"Dilatation of Cranial Arteries; MMA, STA and MCA",[485,517],{"nctId":547,"briefTitle":548,"status":256,"phases":549,"primaryCompletion":550,"completion":550,"start":551,"enrollment":261,"conditions":552,"interventions":553},"NCT04853797","Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)",[86],"2025-07-06","2021-05-11",[18,21],[485,554],"Ivabradine",{"nctId":556,"briefTitle":557,"status":256,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":564},"NCT04012047","Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients",[86],"2019-12-10","2019-07-09",17,[18,15,563],"Aura",[485,517],{"nctId":566,"briefTitle":567,"status":256,"phases":568,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":573},"NCT05211050","Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine",[86],"2023-11-05","2022-03-15",24,[21,18],[485,574,517],"Sumatriptan",{"nctId":576,"briefTitle":577,"status":225,"phases":578,"primaryCompletion":579,"completion":579,"start":580,"enrollment":534,"conditions":581,"interventions":582},"NCT05565001","The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.",[86],"2023-07-31","2022-09-01",[18,30,21],[485],{"nctId":584,"briefTitle":585,"status":256,"phases":586,"primaryCompletion":587,"completion":587,"start":588,"enrollment":505,"conditions":589,"interventions":590},"NCT03228355","Headache Inducing Effect of Cromakalim in Migraine Patients",[86],"2017-11-30","2017-05-24",[24],[485,517],{"nctId":592,"briefTitle":593,"status":256,"phases":594,"primaryCompletion":595,"completion":595,"start":596,"enrollment":145,"conditions":597,"interventions":598},"NCT05243953","Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache",[86],"2022-07-07","2022-03-21",[27],[485],{"nctId":600,"briefTitle":601,"status":256,"phases":602,"primaryCompletion":603,"completion":603,"start":604,"enrollment":605,"conditions":606,"interventions":607},"NCT04905654","Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura",[86],"2023-05-16","2021-09-29",35,[24,563],[485,517],{"intervention":517,"totalTrials":450,"cells":609},{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":611,"activeCount":93},[],{"trials":613,"activeCount":93},[],{"trials":615,"activeCount":93},[],{"trials":617,"activeCount":93},[],{"trials":619,"activeCount":93},[],{"trials":621,"activeCount":93},[622,630,634,638,642,651,660,664,674,678,682,686],{"nctId":623,"briefTitle":624,"status":256,"phases":625,"primaryCompletion":626,"completion":626,"start":523,"enrollment":12,"conditions":627,"interventions":628},"NCT03887325","The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients",[86],"2020-02-29",[24],[629,517],"Maxipost",{"nctId":509,"briefTitle":510,"status":256,"phases":631,"primaryCompletion":512,"completion":512,"start":513,"enrollment":514,"conditions":632,"interventions":633},[86],[263],[485,517],{"nctId":519,"briefTitle":520,"status":225,"phases":635,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":636,"interventions":637},[86],[526,18,527],[485,517],{"nctId":530,"briefTitle":531,"status":256,"phases":639,"primaryCompletion":472,"completion":472,"start":533,"enrollment":534,"conditions":640,"interventions":641},[86],[136,485],[485,517],{"nctId":643,"briefTitle":644,"status":256,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":22,"conditions":648,"interventions":649},"NCT04577443","The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties.",[86],"2021-10-30","2020-11-01",[24],[650,517],"Adenosine",{"nctId":652,"briefTitle":653,"status":225,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":505,"conditions":657,"interventions":658},"NCT04744129","Headache Inducing Effect of NN414 in Migraine Patients",[86],"2023-02","2022-02-25",[24],[659,517],"NN414",{"nctId":538,"briefTitle":539,"status":256,"phases":661,"primaryCompletion":541,"completion":541,"start":542,"enrollment":534,"conditions":662,"interventions":663},[86],[544,18],[485,517],{"nctId":665,"briefTitle":666,"status":256,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":534,"conditions":671,"interventions":672},"NCT03471039","PACAP27 Headache Properties in Migraine Without Aura Patients",[86],"2018-08-30","2018-09-30","2017-08-30",[21],[673,517],"PACAP27",{"nctId":556,"briefTitle":557,"status":256,"phases":675,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":676,"interventions":677},[86],[18,15,563],[485,517],{"nctId":566,"briefTitle":567,"status":256,"phases":679,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":680,"interventions":681},[86],[21,18],[485,574,517],{"nctId":584,"briefTitle":585,"status":256,"phases":683,"primaryCompletion":587,"completion":587,"start":588,"enrollment":505,"conditions":684,"interventions":685},[86],[24],[485,517],{"nctId":600,"briefTitle":601,"status":256,"phases":687,"primaryCompletion":603,"completion":603,"start":604,"enrollment":605,"conditions":688,"interventions":689},[86],[24,563],[485,517],{"intervention":574,"totalTrials":691,"cells":692},5,{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":694,"activeCount":93},[],{"trials":696,"activeCount":93},[],{"trials":698,"activeCount":93},[],{"trials":700,"activeCount":93},[],{"trials":702,"activeCount":93},[],{"trials":704,"activeCount":93},[705,714,723,731,740],{"nctId":706,"briefTitle":707,"status":256,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":713},"NCT03156920","Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers",[86],"2017-10-18","2017-05-23",30,[15],[574],{"nctId":715,"briefTitle":716,"status":256,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":505,"conditions":720,"interventions":721},"NCT00399633","Neuropeptides in the Humane Intra- og Extracerebral Circulation.",[86],"2007-04","2007-01",[35,15],[722],"sumatriptan",{"nctId":724,"briefTitle":725,"status":256,"phases":726,"primaryCompletion":727,"completion":727,"start":260,"enrollment":711,"conditions":728,"interventions":729},"NCT02486276","The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache",[86],"2016-06",[15],[730,574],"Cilostazol",{"nctId":732,"briefTitle":733,"status":256,"phases":734,"primaryCompletion":735,"completion":735,"start":736,"enrollment":711,"conditions":737,"interventions":738},"NCT02485340","The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache",[86],"2015-08","2015-04",[15],[739,574],"5-ISMN",{"nctId":566,"briefTitle":567,"status":256,"phases":741,"primaryCompletion":569,"completion":569,"start":570,"enrollment":571,"conditions":742,"interventions":743},[86],[21,18],[485,574,517],{"intervention":730,"totalTrials":691,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":754,"NA":756},{"trials":747,"activeCount":93},[],{"trials":749,"activeCount":93},[],{"trials":751,"activeCount":93},[],{"trials":753,"activeCount":93},[],{"trials":755,"activeCount":93},[],{"trials":757,"activeCount":93},[758,765,769,779,788],{"nctId":759,"briefTitle":760,"status":225,"phases":761,"primaryCompletion":227,"completion":227,"start":762,"enrollment":145,"conditions":763,"interventions":764},"NCT05595993","Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache",[86],"2022-10-25",[27],[730],{"nctId":724,"briefTitle":725,"status":256,"phases":766,"primaryCompletion":727,"completion":727,"start":260,"enrollment":711,"conditions":767,"interventions":768},[86],[15],[730,574],{"nctId":770,"briefTitle":771,"status":256,"phases":772,"primaryCompletion":773,"completion":773,"start":735,"enrollment":774,"conditions":775,"interventions":777},"NCT02549898","Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI",[86],"2018-06",34,[776,21],"Migraine Headache",[778,730],"Feraheme",{"nctId":780,"briefTitle":781,"status":256,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":787},"NCT01841827","The Headache Inducing Effects of Cilostazol on Migraine Patients",[86],"2013-06","2013-04",14,[15],[730],{"nctId":789,"briefTitle":790,"status":225,"phases":791,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT04452929","The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients",[86],"2022-02","2022-07","2020-07-22",72,[15,21,30],[408,798,730],"Calcitonin gene-related peptide",{"intervention":800,"totalTrials":691,"cells":801},"Calcitonin Gene-Related Peptide",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":820},{"trials":803,"activeCount":93},[],{"trials":805,"activeCount":93},[],{"trials":807,"activeCount":93},[],{"trials":809,"activeCount":93},[],{"trials":811,"activeCount":93},[812],{"nctId":813,"briefTitle":814,"status":225,"phases":815,"primaryCompletion":144,"completion":144,"start":816,"enrollment":817,"conditions":818,"interventions":819},"NCT04592952","Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab",[85],"2020-10-08",400,[15],[800,408],{"trials":821,"activeCount":93},[822,830,839,849],{"nctId":823,"briefTitle":824,"status":225,"phases":825,"primaryCompletion":826,"completion":826,"start":827,"enrollment":331,"conditions":828,"interventions":829},"NCT03481400","CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment",[86],"2019-09","2016-07",[15],[800],{"nctId":831,"briefTitle":832,"status":225,"phases":833,"primaryCompletion":259,"completion":834,"start":835,"enrollment":16,"conditions":836,"interventions":837},"NCT03143465","Pharmacologically Triggered Migraine Without Aura and Neuroimaging",[86],"2019-05","2016-08",[30],[800,838],"Sildenafil",{"nctId":840,"briefTitle":841,"status":256,"phases":842,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":848},"NCT03791515","Clinical Characteristics and Pathophysiology of Post-Traumatic Headache",[86],"2019-12-01","2018-07-26",200,[27,847],"Concussion, Mild",[800],{"nctId":789,"briefTitle":790,"status":225,"phases":850,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":851,"interventions":852},[86],[15,21,30],[408,798,730],{"intervention":408,"totalTrials":691,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":865,"PHASE4":867,"NA":891},{"trials":856,"activeCount":93},[],{"trials":858,"activeCount":93},[],{"trials":860,"activeCount":93},[861],{"nctId":399,"briefTitle":400,"status":225,"phases":862,"primaryCompletion":402,"completion":403,"start":404,"enrollment":105,"conditions":863,"interventions":864},[83],[406],[408,390],{"trials":866,"activeCount":93},[],{"trials":868,"activeCount":93},[869,878,887],{"nctId":870,"briefTitle":871,"status":225,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":877},"NCT04674020","Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment",[85],"2025-07-22","2020-10-22",250,[15,18],[408],{"nctId":879,"briefTitle":880,"status":225,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":886},"NCT04603976","Registry for Migraine - Clinical Core",[85],"2022-10","2020-09-25",1000,[15],[408],{"nctId":813,"briefTitle":814,"status":225,"phases":888,"primaryCompletion":144,"completion":144,"start":816,"enrollment":817,"conditions":889,"interventions":890},[85],[15],[800,408],{"trials":892,"activeCount":93},[893],{"nctId":789,"briefTitle":790,"status":225,"phases":894,"primaryCompletion":792,"completion":793,"start":794,"enrollment":795,"conditions":895,"interventions":896},[86],[15,21,30],[408,798,730],{"intervention":898,"totalTrials":899,"cells":900},"CGRP",4,{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":902,"activeCount":93},[],{"trials":904,"activeCount":93},[],{"trials":906,"activeCount":93},[],{"trials":908,"activeCount":93},[],{"trials":910,"activeCount":93},[],{"trials":912,"activeCount":93},[913,922,929,937],{"nctId":914,"briefTitle":915,"status":256,"phases":916,"primaryCompletion":917,"completion":917,"start":918,"enrollment":711,"conditions":919,"interventions":921},"NCT00687947","Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)",[86],"2008-08","2008-05",[920,30,35],"Familial Hemiplegic Migraine",[898],{"nctId":923,"briefTitle":924,"status":256,"phases":925,"primaryCompletion":926,"completion":926,"start":783,"enrollment":331,"conditions":927,"interventions":928},"NCT01924052","CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load",[86],"2013-08",[21],[898],{"nctId":930,"briefTitle":931,"status":256,"phases":932,"completion":933,"start":934,"enrollment":534,"conditions":935,"interventions":936},"NCT00358839","Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.",[86],"2006-10","2006-07",[920],[898],{"nctId":938,"briefTitle":939,"status":256,"phases":940,"primaryCompletion":941,"completion":942,"start":943,"enrollment":534,"conditions":944,"interventions":945},"NCT04231617","The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers",[86],"2020-08-01","2020-09-01","2020-01-20",[526,18,527],[946,898],"glibenclamide",{"intervention":838,"totalTrials":948,"cells":949},3,{"EARLY_PHASE1":950,"PHASE1":952,"PHASE2":954,"PHASE3":956,"PHASE4":958,"NA":960},{"trials":951,"activeCount":93},[],{"trials":953,"activeCount":93},[],{"trials":955,"activeCount":93},[],{"trials":957,"activeCount":93},[],{"trials":959,"activeCount":93},[],{"trials":961,"activeCount":93},[962,970,974],{"nctId":963,"briefTitle":964,"status":256,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":505,"conditions":968,"interventions":969},"NCT05889455","Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab",[86],"2023-10-12","2023-04-20",[21],[838],{"nctId":831,"briefTitle":832,"status":225,"phases":971,"primaryCompletion":259,"completion":834,"start":835,"enrollment":16,"conditions":972,"interventions":973},[86],[30],[800,838],{"nctId":975,"briefTitle":976,"status":225,"phases":977,"primaryCompletion":227,"completion":227,"start":978,"enrollment":145,"conditions":979,"interventions":980},"NCT05669885","Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache",[86],"2023-01-02",[27],[838],{"intervention":982,"totalTrials":9,"cells":983},"Imigran",{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":992,"NA":994},{"trials":985,"activeCount":93},[],{"trials":987,"activeCount":93},[],{"trials":989,"activeCount":93},[],{"trials":991,"activeCount":93},[],{"trials":993,"activeCount":93},[],{"trials":995,"activeCount":93},[996,1004],{"nctId":997,"briefTitle":998,"status":256,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":261,"conditions":1002,"interventions":1003},"NCT03881644","PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine",[86],"2019-12-07","2018-07-17",[21],[982],{"nctId":1005,"briefTitle":1006,"status":256,"phases":1007,"primaryCompletion":1008,"completion":1008,"start":1009,"enrollment":1010,"conditions":1011,"interventions":1013},"NCT03878784","PACAP38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea",[86],"2019-12-19","2018-11-12",38,[1012],"Rosacea",[982],{"intervention":629,"totalTrials":9,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1017,"activeCount":93},[],{"trials":1019,"activeCount":93},[],{"trials":1021,"activeCount":93},[],{"trials":1023,"activeCount":93},[],{"trials":1025,"activeCount":93},[],{"trials":1027,"activeCount":93},[1028,1032],{"nctId":623,"briefTitle":624,"status":256,"phases":1029,"primaryCompletion":626,"completion":626,"start":523,"enrollment":12,"conditions":1030,"interventions":1031},[86],[24],[629,517],{"nctId":1033,"briefTitle":1034,"status":225,"phases":1035,"primaryCompletion":227,"completion":227,"start":580,"enrollment":145,"conditions":1036,"interventions":1037},"NCT05378074","Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache",[86],[27],[629],{"intervention":946,"totalTrials":9,"cells":1039},{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1041,"activeCount":93},[],{"trials":1043,"activeCount":93},[],{"trials":1045,"activeCount":93},[],{"trials":1047,"activeCount":93},[],{"trials":1049,"activeCount":93},[],{"trials":1051,"activeCount":93},[1052,1062],{"nctId":1053,"briefTitle":1054,"status":256,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1060},"NCT04960657","The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers",[86],"2021-03-19","2020-10-20",22,[15,18,136],[946,1061],"PACAP38",{"nctId":938,"briefTitle":939,"status":256,"phases":1063,"primaryCompletion":941,"completion":942,"start":943,"enrollment":534,"conditions":1064,"interventions":1065},[86],[526,18,527],[946,898],{"intervention":1061,"totalTrials":9,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1078},{"trials":1069,"activeCount":93},[],{"trials":1071,"activeCount":93},[],{"trials":1073,"activeCount":93},[],{"trials":1075,"activeCount":93},[],{"trials":1077,"activeCount":93},[],{"trials":1079,"activeCount":93},[1080,1084],{"nctId":1053,"briefTitle":1054,"status":256,"phases":1081,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":1058,"conditions":1082,"interventions":1083},[86],[15,18,136],[946,1061],{"nctId":1085,"briefTitle":1086,"status":256,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":450,"conditions":1090,"interventions":1091},"NCT00380263","PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow",[86],"2007-11","2006-11",[21],[1061],{"intervention":1093,"totalTrials":9,"cells":1094},"Carbachol",{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1096,"activeCount":93},[],{"trials":1098,"activeCount":93},[],{"trials":1100,"activeCount":93},[],{"trials":1102,"activeCount":93},[],{"trials":1104,"activeCount":93},[],{"trials":1106,"activeCount":93},[1107,1116],{"nctId":1108,"briefTitle":1109,"status":256,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":450,"conditions":1114,"interventions":1115},"NCT00564408","Carbachols Headache-inducing Effect and Changes in Cerebral Blood Flow in Migraine Patients",[86],"2008-10","2009-02","2007-08",[18],[1093],{"nctId":1117,"briefTitle":1118,"status":256,"phases":1119,"completion":718,"start":934,"enrollment":524,"conditions":1120,"interventions":1121},"NCT00357864","Carbachol´s Headache Inducing Characteristics and Effects on the Cerebral Blood Flow",[],[18],[1122],"carbachol",{"intervention":1124,"totalTrials":9,"cells":1125},"Riociguat",{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1127,"activeCount":93},[],{"trials":1129,"activeCount":93},[],{"trials":1131,"activeCount":93},[],{"trials":1133,"activeCount":93},[],{"trials":1135,"activeCount":93},[],{"trials":1137,"activeCount":93},[1138,1146],{"nctId":1139,"briefTitle":1140,"status":256,"phases":1141,"primaryCompletion":1142,"completion":1142,"start":1143,"enrollment":1058,"conditions":1144,"interventions":1145},"NCT05750446","Effect of Riocigaut on Migraine Attack Induction in People With Migraine",[86],"2024-02-01","2023-06-01",[21],[1124],{"nctId":1147,"briefTitle":1148,"status":256,"phases":1149,"primaryCompletion":1143,"completion":1143,"start":1150,"enrollment":524,"conditions":1151,"interventions":1152},"NCT05582811","Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers",[86],"2022-10-26",[18],[1153,1124],"Dose Riociguat 2,5 or 5mg",{"intervention":1155,"totalTrials":89,"cells":1156},"Vasoactive Intestinal Polypeptide",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1158,"activeCount":93},[],{"trials":1160,"activeCount":93},[],{"trials":1162,"activeCount":93},[],{"trials":1164,"activeCount":93},[],{"trials":1166,"activeCount":93},[],{"trials":1168,"activeCount":93},[1169],{"nctId":1170,"briefTitle":1171,"status":256,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":145,"conditions":1175,"interventions":1176},"NCT04260035","The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients",[86],"2020-09-15","2020-05-19",[15,136,193,139,134,135],[1155,1177],"Sterile saline",{"intervention":1177,"totalTrials":89,"cells":1179},{"EARLY_PHASE1":1180,"PHASE1":1182,"PHASE2":1184,"PHASE3":1186,"PHASE4":1188,"NA":1190},{"trials":1181,"activeCount":93},[],{"trials":1183,"activeCount":93},[],{"trials":1185,"activeCount":93},[],{"trials":1187,"activeCount":93},[],{"trials":1189,"activeCount":93},[],{"trials":1191,"activeCount":93},[1192],{"nctId":1170,"briefTitle":1171,"status":256,"phases":1193,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":145,"conditions":1194,"interventions":1195},[86],[15,136,193,139,134,135],[1155,1177],{"intervention":1197,"totalTrials":89,"cells":1198},"PACAP",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1200,"activeCount":93},[],{"trials":1202,"activeCount":93},[],{"trials":1204,"activeCount":93},[],{"trials":1206,"activeCount":93},[],{"trials":1208,"activeCount":93},[],{"trials":1210,"activeCount":93},[1211],{"nctId":1212,"briefTitle":1213,"status":256,"phases":1214,"primaryCompletion":1215,"completion":1216,"start":1217,"enrollment":1218,"conditions":1219,"interventions":1220},"NCT02158221","PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load",[86],"2014-11","2014-12","2014-06",32,[21],[1197],{"intervention":1222,"totalTrials":89,"cells":1223},"Nitroglycerine",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1225,"activeCount":93},[],{"trials":1227,"activeCount":93},[],{"trials":1229,"activeCount":93},[],{"trials":1231,"activeCount":93},[],{"trials":1233,"activeCount":93},[],{"trials":1235,"activeCount":93},[1236],{"nctId":1237,"briefTitle":1238,"status":256,"phases":1239,"primaryCompletion":918,"completion":918,"start":1240,"enrollment":711,"conditions":1241,"interventions":1242},"NCT00541736","Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine",[86],"2007-10",[920],[1222],{"intervention":1244,"totalTrials":89,"cells":1245},"PGE2",{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1252,"PHASE4":1254,"NA":1256},{"trials":1247,"activeCount":93},[],{"trials":1249,"activeCount":93},[],{"trials":1251,"activeCount":93},[],{"trials":1253,"activeCount":93},[],{"trials":1255,"activeCount":93},[],{"trials":1257,"activeCount":93},[1258],{"nctId":1259,"briefTitle":1260,"status":256,"phases":1261,"start":1262,"enrollment":450,"conditions":1263,"interventions":1264},"NCT00374530","Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2",[86],"2006-08",[18,15],[1244],{"intervention":1266,"totalTrials":89,"cells":1267},"Eptinezumab",{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1269,"activeCount":93},[],{"trials":1271,"activeCount":93},[],{"trials":1273,"activeCount":93},[],{"trials":1275,"activeCount":93},[],{"trials":1277,"activeCount":93},[],{"trials":1279,"activeCount":93},[1280],{"nctId":1281,"briefTitle":1282,"status":256,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1010,"conditions":1286,"interventions":1287},"NCT05635604","Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.",[86],"2023-08-04","2023-03-01",[15],[1266,1288],"PACAP-38",{"intervention":1288,"totalTrials":89,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1299,"NA":1301},{"trials":1292,"activeCount":93},[],{"trials":1294,"activeCount":93},[],{"trials":1296,"activeCount":93},[],{"trials":1298,"activeCount":93},[],{"trials":1300,"activeCount":93},[],{"trials":1302,"activeCount":93},[1303],{"nctId":1281,"briefTitle":1282,"status":256,"phases":1304,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1010,"conditions":1305,"interventions":1306},[86],[15],[1266,1288],{"intervention":1308,"totalTrials":89,"cells":1309},"Vasoactive intestinal peptide",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1311,"activeCount":93},[],{"trials":1313,"activeCount":93},[],{"trials":1315,"activeCount":93},[],{"trials":1317,"activeCount":93},[],{"trials":1319,"activeCount":93},[],{"trials":1321,"activeCount":93},[1322],{"nctId":1323,"briefTitle":1324,"status":256,"phases":1325,"completion":449,"start":1326,"enrollment":450,"conditions":1327,"interventions":1330},"NCT00272896","Hemodynamic and Headache-Inducing Effect of Intravenous Vasoactive Intestinal Peptide in Migraineurs",[86],"2004-10",[18,15,1328,1329],"Vasoactive Intestinal Peptide","Ultrasonography, Doppler, Transcranial",[1308],{"intervention":1332,"totalTrials":89,"cells":1333},"infusion of calcitonin gene related peptide",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1344},{"trials":1335,"activeCount":93},[],{"trials":1337,"activeCount":93},[],{"trials":1339,"activeCount":93},[],{"trials":1341,"activeCount":93},[],{"trials":1343,"activeCount":93},[],{"trials":1345,"activeCount":93},[1346],{"nctId":1347,"briefTitle":1348,"status":256,"phases":1349,"primaryCompletion":1350,"completion":1350,"start":1351,"enrollment":450,"conditions":1352,"interventions":1353},"NCT00363532","Functional MRI (fMRI) in CGRP Induced Migraine",[86],"2007-07","2006-09",[21],[1332],{"intervention":1355,"totalTrials":89,"cells":1356},"Prostaglandin F2alpha",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1358,"activeCount":93},[],{"trials":1360,"activeCount":93},[],{"trials":1362,"activeCount":93},[],{"trials":1364,"activeCount":93},[],{"trials":1366,"activeCount":93},[],{"trials":1368,"activeCount":93},[1369],{"nctId":1370,"briefTitle":1371,"status":256,"phases":1372,"primaryCompletion":379,"completion":379,"start":1373,"enrollment":450,"conditions":1374,"interventions":1375},"NCT01327118","Prostaglandin F2alpha in a Human Headache Model",[86],"2010-09",[18],[1355,1376],"Isoton sodium chloride",{"intervention":1376,"totalTrials":89,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1389},{"trials":1380,"activeCount":93},[],{"trials":1382,"activeCount":93},[],{"trials":1384,"activeCount":93},[],{"trials":1386,"activeCount":93},[],{"trials":1388,"activeCount":93},[],{"trials":1390,"activeCount":93},[1391],{"nctId":1370,"briefTitle":1371,"status":256,"phases":1392,"primaryCompletion":379,"completion":379,"start":1373,"enrollment":450,"conditions":1393,"interventions":1394},[86],[18],[1355,1376],{"intervention":1396,"totalTrials":89,"cells":1397},"Fosphenytoin",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1406,"NA":1408},{"trials":1399,"activeCount":93},[],{"trials":1401,"activeCount":93},[],{"trials":1403,"activeCount":93},[],{"trials":1405,"activeCount":93},[],{"trials":1407,"activeCount":93},[],{"trials":1409,"activeCount":93},[1410],{"nctId":1411,"briefTitle":1412,"status":256,"phases":1413,"primaryCompletion":403,"completion":1414,"start":533,"enrollment":524,"conditions":1415,"interventions":1416},"NCT03712254","Phenytoin as Treatment for Acute Exacerbations of Trigeminal Neuralgia - a Prospective Systematic Study of 20 Patients",[],"2021-11-01",[406],[1396],{"intervention":1418,"totalTrials":89,"cells":1419},"Calcitonin Gene Related Peptide",{"EARLY_PHASE1":1420,"PHASE1":1422,"PHASE2":1424,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1421,"activeCount":93},[],{"trials":1423,"activeCount":93},[],{"trials":1425,"activeCount":93},[],{"trials":1427,"activeCount":93},[],{"trials":1429,"activeCount":93},[],{"trials":1431,"activeCount":93},[1432],{"nctId":1433,"briefTitle":1434,"status":256,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":711,"conditions":1438,"interventions":1439},"NCT03542357","The Effect of Sumatriptan and Placebo on CGRP Induced Headache",[86],"2018-09-01","2018-02-15",[15],[1418,1440],"Sumatriptan 50 mg",{"intervention":1440,"totalTrials":89,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1444,"activeCount":93},[],{"trials":1446,"activeCount":93},[],{"trials":1448,"activeCount":93},[],{"trials":1450,"activeCount":93},[],{"trials":1452,"activeCount":93},[],{"trials":1454,"activeCount":93},[1455],{"nctId":1433,"briefTitle":1434,"status":256,"phases":1456,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":711,"conditions":1457,"interventions":1458},[86],[15],[1418,1440],{"intervention":1460,"totalTrials":89,"cells":1461},"Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1468,"PHASE4":1470,"NA":1472},{"trials":1463,"activeCount":93},[],{"trials":1465,"activeCount":93},[],{"trials":1467,"activeCount":93},[],{"trials":1469,"activeCount":93},[],{"trials":1471,"activeCount":93},[],{"trials":1473,"activeCount":93},[1474],{"nctId":1475,"briefTitle":1476,"status":256,"phases":1477,"primaryCompletion":1478,"completion":1478,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1482},"NCT04218760","Multiomics After Headache Provocation of People Who Are Unable to Have Headache",[86],"2020-03-12","2019-10-10",58,[18,35],[1460],{"intervention":1484,"totalTrials":89,"cells":1485},"GTN",{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1487,"activeCount":93},[],{"trials":1489,"activeCount":93},[],{"trials":1491,"activeCount":93},[],{"trials":1493,"activeCount":93},[],{"trials":1495,"activeCount":93},[],{"trials":1497,"activeCount":93},[1498],{"nctId":1499,"briefTitle":1500,"status":256,"phases":1501,"completion":1502,"start":1503,"enrollment":711,"conditions":1504,"interventions":1507},"NCT00257985","Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2",[86],"2006-03","2005-04",[1505,1506],"Familial Hemiplegic Migraine Type 1 and 2","Healthy Volunteers",[1484],{"intervention":1509,"totalTrials":89,"cells":1510},"Glyceryl trinitrate, azetazolamide",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1512,"activeCount":93},[],{"trials":1514,"activeCount":93},[],{"trials":1516,"activeCount":93},[],{"trials":1518,"activeCount":93},[],{"trials":1520,"activeCount":93},[],{"trials":1522,"activeCount":93},[1523],{"nctId":1524,"briefTitle":1525,"status":225,"phases":1526,"completion":1527,"enrollment":450,"conditions":1528,"interventions":1529},"NCT00363792","Effect of GTN and Diamox Measured by BOLD-Response.",[86],"2007-05",[35],[1509],{"intervention":1531,"totalTrials":89,"cells":1532},"Acetazolamide",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1539,"PHASE4":1541,"NA":1543},{"trials":1534,"activeCount":93},[],{"trials":1536,"activeCount":93},[],{"trials":1538,"activeCount":93},[],{"trials":1540,"activeCount":93},[],{"trials":1542,"activeCount":93},[],{"trials":1544,"activeCount":93},[1545],{"nctId":1546,"briefTitle":1547,"status":256,"phases":1548,"primaryCompletion":784,"completion":784,"start":1549,"enrollment":450,"conditions":1550,"interventions":1551},"NCT01750723","Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow",[86],"2012-12",[18,15],[1531],{"intervention":739,"totalTrials":89,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1555,"activeCount":93},[],{"trials":1557,"activeCount":93},[],{"trials":1559,"activeCount":93},[],{"trials":1561,"activeCount":93},[],{"trials":1563,"activeCount":93},[],{"trials":1565,"activeCount":93},[1566],{"nctId":732,"briefTitle":733,"status":256,"phases":1567,"primaryCompletion":735,"completion":735,"start":736,"enrollment":711,"conditions":1568,"interventions":1569},[86],[15],[739,574],{"intervention":650,"totalTrials":89,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1573,"activeCount":93},[],{"trials":1575,"activeCount":93},[],{"trials":1577,"activeCount":93},[],{"trials":1579,"activeCount":93},[],{"trials":1581,"activeCount":93},[],{"trials":1583,"activeCount":93},[1584],{"nctId":643,"briefTitle":644,"status":256,"phases":1585,"primaryCompletion":646,"completion":646,"start":647,"enrollment":22,"conditions":1586,"interventions":1587},[86],[24],[650,517],{"intervention":1589,"totalTrials":89,"cells":1590},"VIP",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1592,"activeCount":93},[],{"trials":1594,"activeCount":93},[],{"trials":1596,"activeCount":93},[],{"trials":1598,"activeCount":93},[],{"trials":1600,"activeCount":93},[],{"trials":1602,"activeCount":93},[1603],{"nctId":1604,"briefTitle":1605,"status":256,"phases":1606,"completion":1607,"start":1608,"enrollment":450,"conditions":1609,"interventions":1611},"NCT00255320","Experimental Headache Induced by Vasoactive Intestinal Polypeptide",[86],"2004-06","2003-12",[1610],"Healthy Volunteers, Headache, Migraine, Hemodynamics, VIP, SPECT, Ultrasound",[1589],{"intervention":659,"totalTrials":89,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1615,"activeCount":93},[],{"trials":1617,"activeCount":93},[],{"trials":1619,"activeCount":93},[],{"trials":1621,"activeCount":93},[],{"trials":1623,"activeCount":93},[],{"trials":1625,"activeCount":93},[1626],{"nctId":652,"briefTitle":653,"status":225,"phases":1627,"primaryCompletion":655,"completion":655,"start":656,"enrollment":505,"conditions":1628,"interventions":1629},[86],[24],[659,517],{"intervention":554,"totalTrials":89,"cells":1631},{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1633,"activeCount":93},[],{"trials":1635,"activeCount":93},[],{"trials":1637,"activeCount":93},[],{"trials":1639,"activeCount":93},[],{"trials":1641,"activeCount":93},[],{"trials":1643,"activeCount":93},[1644],{"nctId":547,"briefTitle":548,"status":256,"phases":1645,"primaryCompletion":550,"completion":550,"start":551,"enrollment":261,"conditions":1646,"interventions":1647},[86],[18,21],[485,554],{"intervention":1649,"totalTrials":89,"cells":1650},"Vasoactive Intestinal Peptide (VIP) and Saline",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1652,"activeCount":93},[],{"trials":1654,"activeCount":93},[],{"trials":1656,"activeCount":93},[],{"trials":1658,"activeCount":93},[],{"trials":1660,"activeCount":93},[],{"trials":1662,"activeCount":93},[1663],{"nctId":1664,"briefTitle":1665,"status":256,"phases":1666,"primaryCompletion":1667,"completion":1667,"start":1668,"enrollment":450,"conditions":1669,"interventions":1670},"NCT03989817","The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers",[86],"2020-06-30","2019-06-14",[33],[1649],{"intervention":778,"totalTrials":89,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1674,"activeCount":93},[],{"trials":1676,"activeCount":93},[],{"trials":1678,"activeCount":93},[],{"trials":1680,"activeCount":93},[],{"trials":1682,"activeCount":93},[],{"trials":1684,"activeCount":93},[1685],{"nctId":770,"briefTitle":771,"status":256,"phases":1686,"primaryCompletion":773,"completion":773,"start":735,"enrollment":774,"conditions":1687,"interventions":1688},[86],[776,21],[778,730],{"intervention":673,"totalTrials":89,"cells":1690},{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1695,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1692,"activeCount":93},[],{"trials":1694,"activeCount":93},[],{"trials":1696,"activeCount":93},[],{"trials":1698,"activeCount":93},[],{"trials":1700,"activeCount":93},[],{"trials":1702,"activeCount":93},[1703],{"nctId":665,"briefTitle":666,"status":256,"phases":1704,"primaryCompletion":668,"completion":669,"start":670,"enrollment":534,"conditions":1705,"interventions":1706},[86],[21],[673,517],{"intervention":1708,"totalTrials":89,"cells":1709},"GTN, Diamox",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1711,"activeCount":93},[],{"trials":1713,"activeCount":93},[],{"trials":1715,"activeCount":93},[],{"trials":1717,"activeCount":93},[],{"trials":1719,"activeCount":93},[],{"trials":1721,"activeCount":93},[1722],{"nctId":1723,"briefTitle":1724,"status":225,"phases":1725,"completion":1527,"start":1262,"enrollment":450,"conditions":1726,"interventions":1727},"NCT00363571","The Effect of Glyceryl Trinitate and Diamox on Cerebral Haemodynamics.",[86],[15],[1708],{"intervention":1729,"totalTrials":89,"cells":1730},"Candesartan",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1741},{"trials":1732,"activeCount":93},[],{"trials":1734,"activeCount":93},[],{"trials":1736,"activeCount":93},[],{"trials":1738,"activeCount":93},[],{"trials":1740,"activeCount":93},[],{"trials":1742,"activeCount":93},[1743],{"nctId":1744,"briefTitle":1745,"status":256,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":1480,"conditions":1749,"interventions":1750},"NCT05328635","Post-traumatic Headache Multidisciplinary Study",[],"2024-09-01","2021-09-01",[27,357],[1729],{"intervention":1752,"totalTrials":89,"cells":1753},"Natriuretic peptides",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1755,"activeCount":93},[],{"trials":1757,"activeCount":93},[],{"trials":1759,"activeCount":93},[],{"trials":1761,"activeCount":93},[],{"trials":1763,"activeCount":93},[],{"trials":1765,"activeCount":93},[1766],{"nctId":1767,"briefTitle":1768,"status":256,"phases":1769,"primaryCompletion":1770,"start":1771,"enrollment":11,"conditions":1772,"interventions":1773},"NCT01637662","Natriuretic Peptide's Headache Inducing Characteristics and Effects on the Cerebral Blood Flow",[86],"2014-01","2012-07",[18,15],[1752],{"intervention":1775,"totalTrials":89,"cells":1776},"Cilostazol 200mg",{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1778,"activeCount":93},[],{"trials":1780,"activeCount":93},[],{"trials":1782,"activeCount":93},[],{"trials":1784,"activeCount":93},[],{"trials":1786,"activeCount":93},[],{"trials":1788,"activeCount":93},[1789],{"nctId":1790,"briefTitle":1791,"status":256,"phases":1792,"primaryCompletion":1436,"completion":1436,"start":1793,"enrollment":711,"conditions":1794,"interventions":1795},"NCT03422796","The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache",[86],"2017-11-01",[15],[1775,1796],"SUMAtriptan 6 MG\u002FML",{"intervention":1796,"totalTrials":89,"cells":1798},{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1805,"PHASE4":1807,"NA":1809},{"trials":1800,"activeCount":93},[],{"trials":1802,"activeCount":93},[],{"trials":1804,"activeCount":93},[],{"trials":1806,"activeCount":93},[],{"trials":1808,"activeCount":93},[],{"trials":1810,"activeCount":93},[1811],{"nctId":1790,"briefTitle":1791,"status":256,"phases":1812,"primaryCompletion":1436,"completion":1436,"start":1793,"enrollment":711,"conditions":1813,"interventions":1814},[86],[15],[1775,1796],{"intervention":1816,"totalTrials":89,"cells":1817},"Isosorbide Mononitrate 60 MG",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1819,"activeCount":93},[],{"trials":1821,"activeCount":93},[],{"trials":1823,"activeCount":93},[],{"trials":1825,"activeCount":93},[],{"trials":1827,"activeCount":93},[],{"trials":1829,"activeCount":93},[1830],{"nctId":1831,"briefTitle":1832,"status":256,"phases":1833,"primaryCompletion":1478,"completion":1478,"start":1834,"enrollment":1480,"conditions":1835,"interventions":1836},"NCT04217668","Headache Provocation of People Who Are Unable to Have Headache",[86],"2019-12-02",[18,35],[1816],{"intervention":1838,"totalTrials":89,"cells":1839},"Amitriptyline",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1841,"activeCount":93},[],{"trials":1843,"activeCount":93},[],{"trials":1845,"activeCount":93},[],{"trials":1847,"activeCount":93},[],{"trials":1849,"activeCount":93},[],{"trials":1851,"activeCount":93},[1852],{"nctId":1853,"briefTitle":1854,"status":256,"phases":1855,"primaryCompletion":1856,"completion":1856,"start":1857,"enrollment":1858,"conditions":1859,"interventions":1861},"NCT02746250","Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache.",[86],"2017-01","2016-03",46,[1860],"Tension-type Headache",[1838],{"intervention":1153,"totalTrials":89,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1865,"activeCount":93},[],{"trials":1867,"activeCount":93},[],{"trials":1869,"activeCount":93},[],{"trials":1871,"activeCount":93},[],{"trials":1873,"activeCount":93},[],{"trials":1875,"activeCount":93},[1876],{"nctId":1147,"briefTitle":1148,"status":256,"phases":1877,"primaryCompletion":1143,"completion":1143,"start":1150,"enrollment":524,"conditions":1878,"interventions":1879},[86],[18],[1153,1124]]